Encelta T-cell therapy target and eliminate both blood cancers and solid tumors combined with bispecific antibodies.
Encelta has raised $1.7M in total funding. The most recent round was Grant. The last funding was announced in May 2025.
Encelta's investors include Innosuisse.
Encelta is headquartered in Basel, Switzerland.
Encelta T-cell therapy target and eliminate both blood cancers and solid tumors combined with bispecific antibodies.
Encelta is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Encelta — Funding & Investors." VCBacked, May 19, 2025, https://www.vcbacked.co/company/encelta. Accessed October 6, 2026.
VCBacked. (2025). Encelta — Funding & Investors. Retrieved October 6, 2026, from https://www.vcbacked.co/company/encelta
{{cite web |title=Encelta — Funding & Investors |url=https://www.vcbacked.co/company/encelta |website=VCBacked |access-date=October 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated